Benefits of 2D-LC/MS/MS in Pharmaceutical Bioanalytics

| June 25, 2019

article image
This application demonstrates the 2D-LC/MS/MS analysis of cell supernatants from an in vitro cell suspension-based assay. Superior separation by 2D-LC allowed the analysis of 16 target metabolites within 35 minutes.

Spotlight

Hitachi Healthcare Americas

Hitachi Healthcare Americas delivers best in class medical imaging technologies for healthcare providers. Hitachi’s MRI, CT and Ultrasound provide speed, comfort and quality for both physicians and patients and play an important role in the diagnosis and treatment of disease while driving social innovation into healthcare. Our technologies enable unrivalled flexibility in positioning and streamlined workflows for technologists and physicians while allowing patients to be more comfortable resulting in a more cooperative patient and better imaging results. Physicians can grow their business into pediatrics, orthopedics and other unique patient populations while exploring new areas to compete. With an optimized and patient centric approach healthcare providers can deliver strong value into their communities and Hitachi will be there to support them. Our customer first philosophy compels us to make customer support one of the most important things we do. Innovating Healthcare, Embracing th

OTHER ARTICLES

As Pandemic Continues, Rafael Pharmaceuticals Enrolls Patients in Phase III Pancreatic Cancer Trial

Article | April 17, 2020

That simple truth about the severity of the disease is one of the reasons that Rafael Pharmaceuticals is slowly continuing with a Phase III trial in metastatic pancreatic cancer during the COVID-19 pandemic. While many companies have paused enrollment in clinical trials during the outbreak, Cranbury, N.J,-based Rafael opted to continue to enroll patients in its Phase III AVENGER 500 study of its lead compound CPI-613 (devimistat) in combination with modified Folfirinox (mFFX) as first-line therapy for the disease. Sanjeev Luther, president and chief executive officer of Rafael Pharmaceuticals, told BioSpace that the company made the decision to continue to enroll the trial, which was 75% filled, due to the short timeline patients with metastatic pancreatic cancer have. After discussing the matter of the trial with the company’s leadership team, Luther said they felt comfortable leaving the decision of whether or not the trial should continue to the conducting institute.

Read More

Artificial intelligence in pharma: utilising a valuable resource

Article | April 17, 2020

The pharmaceutical industry is set to greatly benefit from the use of artificial intelligence (AI), due to its wide range of applications. Sydney Tierney discusses how machine learning can enhance marketing, manufacturing and drug trials. Artificial intelligence (AI) can be applied to nearly every aspect of the pharmaceutical and healthcare industry, to enhance data processing. Adopting the technology will reveal the astonishing potential of the healthcare sector, with success rates flying higher than ever before – especially in the research and development of crucial, life-changing drugs.

Read More

Do Clinical Trial Delays Mean Trouble for Pharmaceutical Stocks?

Article | April 17, 2020

Pharmaceutical stocks have been somewhat of a safe haven for investors as the coronavirus outbreak spread from China to the rest of the world. But as the pandemic deepened, now resulting in more than 782,000 cases worldwide, even these "safer" companies are beginning to feel the effects. The U.S. is now the coronavirus epicenter, with the most cases -- more than 161,000 as of today. Initial concerns for drugmakers had to do with the supply of active pharmaceutical ingredients, which often come from China. The worry was that pharmaceutical companies wouldn't be able to produce enough of their drugs for patients.

Read More

3 Big Pharma Stocks Plunging the Most During the Coronavirus Stock Market Crash: Are They Buys?

Article | April 17, 2020

Big pharma stocks have been clobbered during the coronavirus-caused stock market crash. You can count the number of drugmakers with market caps of $25 billion or more whose shares haven't dropped by double-digit percentages on one hand -- and have several fingers left over. Three big pharma stocks have plunged the most: AbbVie (NYSE:ABBV), Bristol Myers Squibb (NYSE:BMY), and Pfizer (NYSE:PFE). But are these stocks smart picks to buy right now?

Read More

Spotlight

Hitachi Healthcare Americas

Hitachi Healthcare Americas delivers best in class medical imaging technologies for healthcare providers. Hitachi’s MRI, CT and Ultrasound provide speed, comfort and quality for both physicians and patients and play an important role in the diagnosis and treatment of disease while driving social innovation into healthcare. Our technologies enable unrivalled flexibility in positioning and streamlined workflows for technologists and physicians while allowing patients to be more comfortable resulting in a more cooperative patient and better imaging results. Physicians can grow their business into pediatrics, orthopedics and other unique patient populations while exploring new areas to compete. With an optimized and patient centric approach healthcare providers can deliver strong value into their communities and Hitachi will be there to support them. Our customer first philosophy compels us to make customer support one of the most important things we do. Innovating Healthcare, Embracing th

Events